amsacrine has been researched along with etoposide in 303 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 58 (19.14) | 18.7374 |
| 1990's | 156 (51.49) | 18.2507 |
| 2000's | 62 (20.46) | 29.6817 |
| 2010's | 26 (8.58) | 24.3611 |
| 2020's | 1 (0.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barrows, LR; Clardy, J; Concepción, GP; Eldredge, GS; Foderaro, TA; Ireland, CM; Lobkovsky, E | 1 |
| Barrows, LR; Eldredge, GS; Ireland, CM; McDonald, LA | 1 |
| Chou, TC; Ciszewska, G; Huang, JT; Kim, JY; Otter, GM; Ren, WY; Sirotnak, FM; Su, TL; Watanabe, KA | 1 |
| Aldous, SC; Coughlin, SA; Dorff, PH; Gruett, MD; Lesher, GY; Rake, JB; Reuman, M; Singh, B; Wentland, MP | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Finlay, GJ; Kaye, AJ | 1 |
| Carmichael, J; Ellis, MJ; Hagan, DJ; Hammonds, TR; Stanslas, J; Stevens, MF; Turner, C; Ward, W | 1 |
| Baguley, BC; Deady, LW; Denny, WA; Rodemann, T; Zhuang, L | 1 |
| Bacsó, Z; Cianfriglia, M; Fenyvesi, F; Goda, K; Kappelmayer, J; Lustyik, G; Nagy, H; Szabó, G; Szilasi, M | 1 |
| Fan, L; Raisch, KP; Shinkre, BA; Velu, SE | 2 |
| Austin, CA; Curtis, H; Gilroy, KL; Jobson, A; López-Lázaro, M; Padget, K; Willmore, E | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chang, IH; Jun, KY; Kwon, Y; Lee, E; Lee, ES; Na, Y; Park, SE | 1 |
| Abdel-Aziz, M; Abuo-Rahma, Gel-D; Kwon, Y; Park, SE; Sayed, MA | 1 |
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZS; Li, D; Li, PH; Mai, YW; Ou, TM; Tan, JH; Yao, PF; Zeng, P | 1 |
| Gao, C; Jiang, Y; Liu, H; Tan, C; Wang, N; Yang, T; Zhang, B; Zhang, W | 1 |
| Bist, G; Jun, KY; Kadayat, TM; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Thapa Magar, TB | 1 |
| Islam, MS; Kadi, AA; Kwon, Y; Park, S; Rahman, AF; Song, C | 1 |
| Infante Lara, L; Laradji, A; Okoro, CO; Osheroff, N; Sledge, A | 1 |
| Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Lee, HJ; Park, S; Shrestha, A; Thapa Magar, TB | 1 |
| Bist, G; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Song, C; Thapa Magar, TB | 1 |
| Cho, WJ; Han, J; Jin, Y; Khadka, DB; Kwon, Y; Park, S | 1 |
| Das, BB; Das, SK; Ghosh, A; Halder, N; Paul Chowdhuri, S; Rath, H; Rehman, I; Sahoo, KC; Sengupta, S | 1 |
| Chen, HX; Dong, CZ; Du, ZY; Huang, ZS; Jiang, H; Li, PH; Li, YL; Tang, YD; Zhang, LY; Zhang, WJ; Zhao, MC; Zhou, W | 1 |
| Gedawy, EM; Kassab, AE | 1 |
| Jang, HJ; Katila, P; Kwon, Y; Lee, ES; Park, S; Shrestha, A; Shrestha, R | 1 |
| Bhattacharya, D; Das, BB; Das, SK; Ghosh, A; Kundu, B; Mukherjee, A; Pal, S; Paul Chowdhuri, S; Sarkar, D; Talukdar, A | 1 |
| Hwang, SY; Jeon, YH; Jeong, TC; Jo, H; Kadayat, TM; Katila, P; Kim, KS; Kim, SK; Koh, WS; Kwon, Y; Lee, ES; Nepal, MR; Noh, K; Park, S; Shrestha, A; Shrestha, R | 1 |
| Dou, Z; He, S; Jin, H; Wang, N; Xiong, Z; Yan, X; Zhang, B | 1 |
| Gabriel, I; Paluszkiewicz, E; Rząd, K | 1 |
| Benson, JD; Huang, ES; Huong, SM; van der Horst, C; Wilson, B | 1 |
| Corbett, AH; DeVore, RF; Osheroff, N | 1 |
| Biersack, H; Boege, F; Gieseler, F; Meyer, P | 2 |
| Kohn, KW; Orr, A; Pommier, Y; Riou, JF | 1 |
| Harbury, P; Jannatipour, M; Liu, YX; Nitiss, JL; Wang, JC; Wasserman, R | 1 |
| Constantinou, A; Grdina, D; Huberman, E; Kiguchi, K | 1 |
| Sumner, AT | 3 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
| Lorico, A; Rappa, G; Sartorelli, AC | 1 |
| Brinch, L; Evensen, SA; Stavem, P; Tjønnfjord, G | 1 |
| Bajko, G; Drozdowska, D; Hansz, J; Woźny, T | 1 |
| Busch, FW; Ehninger, G; Hiddemann, W; Jaschonek, K; Proksch, B; Schleyer, E; Schmidt, H; Schuler, U; Wanner, T | 1 |
| Nakano, H | 1 |
| Beck, WT; Danks, MK | 1 |
| Chresta, CM; Davies, SM; Fry, AM; Harris, AL; Hartley, JA; Hickson, ID; Masters, JR; Walker, MC | 1 |
| Altschuler, E; Chan, D; Hinds, M; Mayes, J; Zwelling, LA | 1 |
| Gewirtz, DA | 1 |
| Lihou, MG; Smith, PJ; Tomlinson, FH | 1 |
| Biersack, H; Boege, F; Clark, M; Gieseler, F | 1 |
| Gray, RG; Rees, JK | 1 |
| Baguley, BC; Finlay, GJ | 2 |
| Beardmore, C; D'Arpa, P; Liu, LF | 1 |
| Kaufmann, SH | 1 |
| Buckley, JD; Hammond, GD; Miller, LP; Pyesmany, AF; Rogers, PC; Siegel, SE; Wells, RJ; Wolff, LJ | 1 |
| Camitta, B; Holbrook, T; Krischer, J; Land, VJ; Sexauer, C; Steuber, CP | 1 |
| Suciu, D | 1 |
| Mandelli, F; Meloni, G | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, B; Harousseau, JL; Ifrah, N; Leprise, PY; Milpied, N | 2 |
| Osheroff, N; Robinson, MJ | 1 |
| Leblanc, J; Sikorska, M; Smith, C; Walker, PR; Whitfield, JF; Youdale, T | 1 |
| Hill, BT; Hinds, MD; Hosking, LK; Mayes, J; Shellard, SA; Whelan, RD; Zwelling, LA | 1 |
| Gilbert, KS; Griswold, DP; Harrison, SD; Laster, WR; Waud, WR | 1 |
| Aller, P; Bernabeu, C; Cabañas, C; Mata, F; Rius, C; Zorrilla, AR | 1 |
| Bastida Vila, P; Giralt López, J; Javier Manchón, G; Olivé Oliveras, T; Ortega Aramburu, JJ; Sánchez, C | 1 |
| De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pinto, MR; Testi, AM; Vegna, ML; Vignetti, M | 1 |
| Granada, I; Las Heras, G; Millá, F; Ribera, JM | 1 |
| de Jong, S; de Vries, EG; Mulder, NH; Zijlstra, JG | 1 |
| Chan, D; Doroshow, JH; Hinds, M; Mayes, J; Meltzer, PS; Parker, E; Sie, KL; Slovak, ML; Trent, JM; Zwelling, LA | 1 |
| Boesen, AM; Brincker, H; Christensen, BE; Drivsholm, A; Ellegaard, J; Hansen, OP; Hippe, E; Jans, H; Jensen, KB; Pedersen-Bjergaard, J | 1 |
| Gupta, R | 1 |
| Bisagni, E; Fossé, P; Nguyen, CH; Paoletti, C; René, B; Saucier, JM | 1 |
| Kawada, S; Nakano, H; Yamashita, Y | 1 |
| Demant, EJ; Hansen, HH; Jensen, PB; Jensen, PS; Sehested, M; Sørensen, BS; Vindeløv, L | 1 |
| Andersson, BS; Ling, YH; Nelson, JA | 1 |
| Mirkes, PE; Zwelling, LA | 1 |
| Elkind, MM; Shibuya, ML; Utsumi, H | 1 |
| Banks, G; Caldecott, K; Jeggo, P | 1 |
| Altschuler, E; Chan, D; Hinds, M; Mayes, J; Zipf, TF; Zwelling, LA | 1 |
| Donhuijsen-Ant, R; Leder, LD; Löffler, H; Schadeck-Gressel, C; Schmidt, U; Westerhausen, M | 1 |
| Briere, J; Casassus, P; Desablens, B; Gandhour, C; Harousseau, JL; Ifrah, N; Le Prise, PY; Milpied, N | 1 |
| Broustet, A; Cony, P; Duclos, F; Marit, G; Puntous, M; Reiffers, J | 1 |
| De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC | 1 |
| Blazka, ME; Henner, WD | 1 |
| Catovsky, D; Chessells, JM; Galton, DA; Goldman, JM; Hann, IM; Hoffbrand, AV; Marcus, RE; Newland, AC; Prentice, HG; Stevens, RF | 1 |
| Gray, R; Hayhoe, FG; Rees, JK | 1 |
| Kort, L; Rowley, R | 1 |
| Berger, NA; Chatterjee, S; Petzold, SJ; Spiridonidis, CA | 1 |
| Evans, HH; Horng, MF; Mencl, J; Ricanati, M | 1 |
| Chan, D; Glisson, BS; Hong, WK; Kim, HK; Sacks, PG; Silberman, L; Zwelling, LA | 1 |
| Epstein, RJ; Smith, PJ | 2 |
| Denyer, SP; Dewick, PM; Figgitt, DP; Jackson, DE; Williams, P | 1 |
| Davies, SL; Davies, SM; Harris, AL; Hickson, ID | 1 |
| Beran, M; Blick, M; Chan, D; Hinds, M; Mayes, J; Parker, E; Radcliffe, A; Sie, KL; Silberman, L; Zwelling, LA | 1 |
| Covey, JM; Holm, C; Kerrigan, D; Pommier, Y | 1 |
| Ford, J; Ganapathi, R; Grabowski, D; Heiss, C; Kerrigan, D; Pommier, Y | 1 |
| Wahlin, A | 1 |
| Goldenberg, GJ; Seneviratne, C | 1 |
| Amadori, S; De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pulsoni, A; Sandrelli, A | 1 |
| Kerrigan, D; Kohn, KW; Pommier, Y | 1 |
| Glisson, BS; Gupta, R; Ross, WE; Sullivan, DM | 1 |
| Bakic, M; Chan, D; Freireich, EJ; Marton, LJ; Zwelling, LA | 1 |
| Andersson, BS; Bakic, M; Beran, M; Chan, D; Estey, E; Ricketts, L; Silberman, L; Zwelling, LA | 1 |
| Covey, JM; Kao-Shan, CS; Kerrigan, D; Pommier, Y; Whang-Peng, J | 1 |
| Beerman, TA; Sigmund, RD; Woynarowski, JM | 1 |
| Bank, B; Forlenza, TJ; Forlenzar, TJ; Grossberg, H; Hsiang, YH; Kanganis, D; Kirschenbaum, S; Liu, LF; Penziner, A; Potmesil, M | 1 |
| Blick, M; Chan, D; Hinds, M; Mayes, J; Silberman, LE; Zwelling, LA | 1 |
| Brecher, ML; Freeman, AI; Green, DM; Sandberg, AA; Simon, JH; Tebbi, CK | 1 |
| Glisson, B; Gupta, R; Ross, W; Smallwood-Kentro, S | 1 |
| Kerrigan, D; McCurdy, A; Pommier, Y; Schwartz, RE; Swack, JA | 1 |
| Glisson, BS; Hodges, PK; Ross, WE; Smallwood-Kentro, S; Sullivan, DM | 1 |
| Esnault, C; Kohn, KW; Le Pecq, JB; Markovits, J; Mattern, MR; Pommier, Y; Roques, BP | 1 |
| Covey, JM; Kerrigan, D; Kohn, KW; Markovits, J; Pommier, Y; Tilchen, EJ | 1 |
| Carter, C; Winfield, DA | 1 |
| Berger, NA; Lazarus, HM | 1 |
| Hiddemann, W; Kreutzmann, H; Maschmeyer, G; Wendt, F | 1 |
| Amadori, S; Avvisati, G; Mandelli, F; Meloni, G; Petti, MC; Tafuri, A | 1 |
| Covelli, A; De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC; Pulsoni, A; Sandrelli, A; Simone, F | 1 |
| Cavalli, F; Fopp, M; Gratwohl, A; Maurice, P; Sauter, C; Tschopp, L; von Fliedner, VE | 1 |
| Child, JA; Franks, CR; Norfolk, DR; Nys, G | 1 |
| Gray, R; Rees, JK | 1 |
| Berthold, F; Creutzig, U; Lampert, F | 1 |
| de Bruïne, FT; Peters, WG; Tham, RT; Willemze, R | 1 |
| Amos, D; Appelbaum, FR; Goldberg, RS; Livingston, RB; Mortimer, J; Tallman, MS; Thomas, ED; Weiden, PL | 1 |
| Berger, NA; Chatterjee, S; Schmotzer, JA; Spiridonidis, CA | 1 |
| Abrams, RA; Anderson, T; Hansen, RM; Hanson, G | 1 |
| Ogawa, M | 2 |
| Andersson, BS; Beran, M; McCredie, KB; Odaimi, M | 1 |
| Brattain, MG; Long, BH; Musial, ST | 1 |
| Hinemann, V; Hoagland, HC; Kovach, JS; Letendre, L | 1 |
| Apostol, JV; Kucuk, O | 1 |
| Abrams, RA; Anderson, T; Baumann, MA; Hansen, R; Hanson, G | 1 |
| Achterrath, W; Balleisen, L; Büchner, T; Hiddemann, W; Preusser, P; Urbanitz, D | 1 |
| Cabanillas, F | 1 |
| Crom, WR; Evans, WE; Hutson, PR; Sinkule, JA; Stewart, CF; Yee, GC | 1 |
| Gahrton, G | 1 |
| Achterrath, W; Balleisen, L; Büchner, T; Hiddemann, W; Kirchhof, B; Preusser, P; Stenzinger, W; Urbanitz, D | 1 |
| Eagan, RT | 1 |
| Klastersky, J; Sculier, JP | 1 |
| Kampinga, HH | 1 |
| Chung, IK; Gootz, TD; McGuirk, PR; Muller, MT; Spitzner, JR | 1 |
| Perry, PE; Slavotinek, A; Sumner, AT | 1 |
| Benchokroun, Y; Larsen, AK; Lelièvre, S | 1 |
| Gromova, II; Razin, SV; Thomsen, B | 1 |
| Astaldi Ricotti, GC; Baas, F; Borst, P; de Haas, M; de Nooij, J; Eijdems, EW; Kamst, E; Timmerman, AJ; Van der Schans, GP | 1 |
| Reilly, JT; Snowden, JA; Wodziński, MA | 1 |
| den Ottolander, GJ; Falkenburg, JH; Fibbe, WE; Kluin-Nelemans, JC; Starrenburg, CW; van der Burgh, JF; Willemze, R; Zijlmans, JM | 1 |
| Carpenter, MS; Choy, J; DeLange, AM; Newsway, VE | 1 |
| Burke, PJ; Cowan, K; Jones, RJ; Karp, JE; Kaufmann, SH; Miller, CB; Schneider, E; Wendel, K; Zwelling, LA | 1 |
| Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B | 1 |
| McMahon, J; Nitiss, JL; Vilalta, PM; Wu, H | 1 |
| Biersack, H; Boege, F; Meyer, P | 1 |
| Ellis, AL; Nowak, B; Plunkett, W; Zwelling, LA | 1 |
| Corbett, AH; Elsea, SH; Osheroff, N; Westergaard, M | 1 |
| Nitiss, JL | 1 |
| Joel, SP; Slevin, ML | 1 |
| Tritton, TR; Vichi, PJ | 1 |
| Inaba, M; Kawada, S; Mitsuhashi, J; Nakano, H | 1 |
| Hsiung, Y; Jannatipour, M; Liu, YX; Nitiss, JL; Yeh, Y | 1 |
| Demant, EJ; Grue, P; Hansen, HH; Jensen, PB; Sehested, M; Sørensen, BS | 1 |
| Aller, P; Pelayo, F; Pérez, C; Vilaboa, NE | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Best-Belpomme, M; Nahon, E; Saucier, JM | 1 |
| Alsner, J; Biersack, H; Boege, F; Gieseler, F; Kjeldsen, E | 1 |
| Berney, JJ; Chresta, CM; Delgado, C; Francis, GE; Patel, P; Tejedor, MC | 1 |
| Daenen, S; Huijgens, PC; Löwenberg, B; Sonneveld, P; van Putten, WL; van Veldhoven, M; Verdonck, LF; Verhoef, G | 1 |
| Kueh, YK; Ong, ST | 1 |
| Delmer, A; Marie, JP; Suberville, AM; Thevenin, D; Zittoun, R | 1 |
| Hsiung, Y; Liu, YX; Nitiss, JL | 1 |
| Bertrand, R; Kohn, KW; Pommier, Y; Solary, E | 1 |
| Boege, F; Gieseler, F; Meyer, P | 1 |
| Boege, F; Clark, M; Gieseler, F; Meyer, P | 1 |
| Corbett, AH; Osheroff, N; Robinson, MJ | 1 |
| Auclair, C; Carteau, S; Goulaouic, H; Mouscadet, JF; Subra, F | 1 |
| Corbett, AH; Hong, D; Osheroff, N | 1 |
| Dilworth, A; Myers, CE; Sinha, BK; Yamazaki, H | 1 |
| Jannatipour, M; Liu, YX; Nitiss, JL | 1 |
| Anachkova, B; Lallev, A; Russev, G | 1 |
| Astaldi Ricotti, GC; Evans, HH; Lanza, A; Pedrini, AM; Ricanati, M; Stefanini, M; Tornaletti, S | 1 |
| Cheng, AL | 1 |
| Elonen, E; Jokipii, A; Lautenschlager, I; Lyytikäinen, O; Ruutu, P; Tiittanen, L | 1 |
| Camitta, B; Holbrook, T; Krischer, J; Land, V; Mahoney, D; Sexauer, C; Steuber, CP; Weinstein, H | 1 |
| An, T; Asano, T; Herzog, CE; Kleinerman, ES; Loughlin, SM; Mayes, J; McWatters, A; Zwelling, LA | 1 |
| Fey, MF; Hardegger, TP; Tobler, A; von Rohr, A | 1 |
| Holm, B; Jensen, PB; Sehested, M | 2 |
| Creus, A; Marcos, R; Ribas, G; Xamena, N | 1 |
| Huismans, DR; Klumper, E; Loonen, AH; Ossenkoppele, GJ; Pieters, R; Rottier, A; Veerman, AJ; Westra, G | 1 |
| Alghisi, GC; Gasser, SM; Vassetzky, YS | 1 |
| An, T; Asano, T; Fojo, AT; Kleinerman, ES; Takano, H; Zwelling, LA | 1 |
| Bernardi, R; Donzelli, M; Negri, C; Scovassi, AI | 1 |
| Avvisati, G; Capria, S; Giona, F; Mandelli, F; Meloni, G; Micozzi, A; Vignetti, M | 1 |
| Nitiss, JL; Wang, JC | 1 |
| Bonanad, S; Carral, A; de la Rubia, J; Jarque, I; Larrea, L; López, F; Martín, G; Martínez, J; Picón, I; Sanz, GF; Sanz, MA; Sempere, A; Soler, MA | 1 |
| Ganapathi, R; Grabowski, D | 1 |
| Aratani, Y; Fujimaki, K; Fujisawa, S; Koyama, H; Motomura, S; Okubo, T | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Ueoka, S; Yamaguchi, M | 1 |
| Dekker, AW; Haak, HL; Huijgens, PC; Löwenberg, B; Ossenkoppele, G; Schouten, HC; Sizoo, W; Sonneveld, P; van der Lelie, J; van Putten, WL; van't Veer, MB; Verdonck, LF; Willemze, R | 1 |
| Burden, DA; Elsea, SH; Lomenick, JP; Osheroff, N; Westergaard, M | 1 |
| Aplan, PD; Chervinsky, DS; Stanulla, M; Wang, J | 1 |
| Baccarani, M; Barillari, G; Cerno, M; Damiani, D; Fanin, R; Geromin, A; Infanti, L; Rinaldi, C; Savignano, C; Silvestri, F; Zaja, F | 1 |
| Brinch, L; Evensen, SA; Hedenus, M; Hörnsten, P; Oberg, G; Simonsson, B; Wahlin, A | 1 |
| Capria, S; Mandelli, F; Meloni, G; Modena, V; Vignetti, M | 1 |
| Falaschi, A; Ochem, A; Phan, TN; Tuteja, N; Tuteja, R | 1 |
| Delaporte, C; Dereuddre, S; Jacquemin-Sablon, A | 1 |
| Fojo, T; Iglesias, A; Matsumoto, M; Matsumoto, Y; Minemura, M; Nagao, S; Takano, H | 1 |
| Aisner, J; Carey, RW; Eaton, WL; Green, MR; Hammond, S; Herndon, JE; Hollis, DR; Maurer, LH; Perry, MC; Skarin, AT; Zacharski, LL | 1 |
| Fojo, T; Iglesias, A; Matsumoto, Y; Nagao, S; Takano, H | 1 |
| Darroudi, F; Mosesso, P; Natarajan, AT; Palitti, F; van den Berg, M; Vermeulen, S | 1 |
| Phan, TN; Tuteja, N | 1 |
| Gray, RG; Hann, IM; Stevens, RF; Wheatley, K | 1 |
| Creus, A; Marcos, R; Torres, C | 1 |
| Carabillò, M; Giuliano, M; Lauricella, M; Tesoriere, G; Vassallo, E; Vento, R | 1 |
| Almqvist, A; Elonen, E; Hänninen, A; Jansson, SE; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Nousiainen, T; Pelliniemi, TT; Rajamäki, A; Remes, K; Ruutu, T; Timonen, T; Vilpo, J; Volin, L | 1 |
| Fojo, T; Kunishio, K; Matsumoto, Y; Morisaki, K; Nagao, S; Takano, H | 1 |
| Burke, PJ; Gore, SD; Weng, LJ | 1 |
| Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R | 1 |
| Bianco, C; Ciardiello, F; Damiano, V; Davies, SL; di Isernia, G; Harris, AL; Hickson, ID; North, P; Pepe, S; Tortora, G | 1 |
| Akan, H; Arat, M; Arslan, O; Beksaç, M; Gürman, G; Ilhan, O; Koç, H; Konuk, N; Ozcan, M; Uysal, A | 1 |
| Avramis, VI; Carcich, S; Ortega, JA; Ozkaynak, MF | 1 |
| Lehman, S; Löfgren, C; Möllgård, L; Paul, C; Sundman-Engberg, B; Tidefelt, U | 1 |
| Feliu, E; Hernández, JA; Millá, F; Navarro, JT; Oriol, A; Pujol, M; Ribera, JM; Sancho, JM | 1 |
| Carabillò, M; Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R | 1 |
| Jensen, PB; Sehested, M; Sorensen, M | 1 |
| Bastow, KF; Vance, JR | 1 |
| Falck, J; Jensen, LH; Jensen, PB; Nitiss, JL; Roerth, M; Rose, A; Sehested, M; Wessel, I | 1 |
| Austin, CA; Baguley, BC; Finlay, GJ; Lock, RB; Meczes, EL; Perenna Rogers, M; Sullivan, DM; Turnbull, RM | 1 |
| Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C | 1 |
| Baccarani, M; Cerno, M; Damiani, D; Fanin, R; Geromin, A; Grimaz, S; Infanti, L; Michieli, M; Savignano, C; Silvestri, F; Skert, C; Sperotto, A | 1 |
| Jacquemin-Sablon, A; Jacquemin-Sablon, H; Khélifa, T; Lambert, B; Le Mée, S; Markovits, J; René, B; Saucier, JM | 1 |
| Austin, CA; Baguley, BC; Errington, F; Li, G; Li, L; Li, W; Tilby, MJ; Willmore, E | 1 |
| Aoyama, M; Bukowski, RM; Ganapathi, MK; Ganapathi, R; Grabowski, DR; Hickson, ID; Holmes, KA; Rybicki, LA; Ye, Y | 1 |
| Abgrall, JF; Audhuy, B; Casassus, P; Deconinck, E; Delain, M; Desablens, B; Guilhot, F; Guyotat, D; Harousseau, JL; Hunault-Berger, M; Le Prise, PY; Lioure, B; Solary, E; Tournilhac, O; Vilque, JP; Witz, B | 1 |
| Balajee, AS; Franchitto, A; Mosesso, P; Palitti, F; Pichierri, P; Proietti de Santis, L | 1 |
| Auparakkitanon, S; Chavalitshewinkoon-Petmitr, P; Pongvilairat, G; Wilairat, P | 1 |
| Fisher, LM; Keller, BA; Patel, S | 1 |
| Boos, G; Stopper, H | 1 |
| Fayers, PM; Girling, DJ; Parmar, MK; Qian, W; Sambrook, RJ; Stephens, RJ | 1 |
| Jensen, LH; Jensen, PB; Møller, M; Nitiss, JL; Sehested, M; Wessel, I | 1 |
| Arimondo, P; Asseline, U; Bailly, C; Boutorine, A; Garestier, T; Hélène, C; Sun, JS | 1 |
| Laroche-Clary, A; Larrue, A; Robert, J | 1 |
| Chan, JK; Cheung, MM; So, JC; Wong, KF | 1 |
| Hsieh, TS; Hu, T; Liu, LF; Mao, Y; Wang, H; Zhou, N | 1 |
| Smith, IE; Stebbing, J | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Aoudjhane, M; Chéron, N; Deloux, J; Douay, L; Elloumi, M; Fouillard, L; Gorin, NC; Guiguet, M; Isnard, F; Laporte, JP; Lesage, S; Lopez, M; Najman, A; Van Den Akker, J; Zunic, P | 1 |
| Kikuchi, A; Nimura, Y; Okada, Y; Suzuki, M; Tosaka, A; Yoshida, S | 1 |
| Fojo, T; Kunishio, K; Matsumoto, Y; Nagao, S; Takano, H | 2 |
| Ganapathi, R; Kleinerman, ES; Zhou, Z; Zwelling, LA | 1 |
| Fojo, T; Matsumoto, Y; Nagao, S; Takano, H | 1 |
| Arimondo, P; Bailly, C; Boukarim, C; Dauzonne, D; Monneret, C | 1 |
| Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Chowdhury, AR; Goswami, A; Majumder, HK; Mandal, S; Mukhopadhyay, S; Sharma, S | 1 |
| Castel, V; Dini, G; Fagioli, F; Ferrant, A; Frassoni, F; Labopin, M; Locatelli, F; Meloni, G; Messina, C; Ortega, J; Pession, A; Shaw, PJ; Sociè, G; Yaniv, I | 1 |
| Kamata, J; Kitoh, K; Kotake, Y; Koyanagi, N; Nagasu, T; Nakamura, K; Niijima, J; Okada, T; Sugumi, H; Uenaka, T; Yamaguchi, A; Yoshimatsu, K; Yoshino, H | 1 |
| Andersson, PO; Brune, M; Gustavsson, B; Stockelberg, D; Wadenvik, H; Wernstedt, P | 1 |
| Aksenov, ND; Poletaev, AI; Shatrova, AN; Zenin, VV | 1 |
| Burnett, AK; Chopra, R; Clark, RE; Culligan, D; Hunter, A; Kell, WJ; Milligan, DW; Prentice, AG; Rohatiner, A; Yin, JA | 1 |
| Austin, CA; Errington, F; Leontiou, C; Tilby, MJ; Willmore, E | 1 |
| Ahlgren, T; Billström, R; Brune, M; Hedenus, M; Höglund, M; Markevärn, B; Nilsson, B; Sallerfors, B; Simonsson, B; Stockelberg, D; Wahlin, A | 1 |
| Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E | 1 |
| Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G | 1 |
| Boiron, JM; Buzyn, A; Delannoy, A; Fegueux, N; Fière, D; Gardin, C; Georges, M; Hacini, M; Huguet, F; Kuentz, M; Lhéritier, V; Micléa, JM; Reman, O; Stamatoullas, A; Thomas, X; Vernant, JP | 1 |
| Bergmann, L; Fischer, JT; Ganser, A; Heil, G; Hoeffken, K; Hoelzer, D; Hofmann, WK; Knuth, A; Koelbel, CB; Kolbe, K; Langer, W; Ottmann, OG; Schmoll, HJ; Westerhausen, M; Wiebe, S; Zander, C | 1 |
| Fowler, P; Parry, EM; Parry, JM; Quick, E | 1 |
| Austin, CA; Lakey, JH; Leontiou, C | 1 |
| Kalaycio, M | 1 |
| Jiang, X | 1 |
| Avvisati, G; Breccia, M; Capria, S; Cimino, G; Diverio, D; Latagliata, R; Meloni, G; Petti, MC | 1 |
| Barbier, M; Bignon, J; Boutonnat, J; Colle, PE; Faussat, AM; Marie, JP; Ronot, X; Thierry, J; Wdzieczak-Bakala, J | 1 |
| Ahn, BM; Baek, JH; Jeon, SB; Kim, DH; Kim, JG; Lee, KB; Moon, JH; Sohn, SK; Sung, WJ | 1 |
| Escherich, G; Hassenpflug, WA; Horstmann, MA; Janka, G; Kabisch, H; zur Stadt, U | 1 |
| Austin, CA; Ayuso, MJ; Azrak, SS; Cortés, F; López-Lázaro, M; Pastor, N | 1 |
| de Graaf, SS; Gibson, BE; Hann, IM; Hills, RK; O'Marcaigh, A; Rao, A; Stiller, C; Webb, DK; Wheatley, K | 1 |
| Aung, L; Kirk, RC; Liang, S; Quah, TC; Tan, RM; Yeoh, AE | 1 |
| Enriquez-Rios, V; Malik, M; Nitiss, JL; Nitiss, KC | 1 |
| Aoun, M; Beguin, H; Georgala, A; Husson, M; Meuleman, N; Nolard, N; Vekemans, M | 1 |
| Goldman, A; Pommier, Y; Sordet, O | 1 |
| Amadori, S; Broccia, G; de Witte, T; Feremans, W; Fillet, G; Jehn, U; Leone, G; Meloni, G; Rio, B; Suciu, S; Thomas, X; Vignetti, M | 1 |
| Hait, WN; Nayak, MS; Yang, JM | 1 |
| Kravchenko, SK; Kremenetskaia, AM; Lorie, IuIu; Obukhova, TN; Vorob'ev, IA; Vorob'ev, VI; Zvonkov, EE | 1 |
| de Bont, ES; Kamps, WA; Koetse, HA; Rings, EH; Stellaard, F; Tissing, WJ; van Vliet, MJ | 1 |
| Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO | 1 |
| Bhosle, J; Hartley, JA; Hochhauser, D; Kiakos, K; Makris, A; Porter, AC; Wu, J | 1 |
| Barber, L; Clay, J; Devlia, V; Feliu, J; Mufti, G; Pagliuca, A; Raj, K; Shaw, B | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Chang, LS; Chen, YJ; Huang, CH; Lee, YC | 1 |
14 review(s) available for amsacrine and etoposide
| Article | Year |
|---|---|
[Antitumor agents targeting mammalian topoisomerases].
Topics: Amsacrine; Animals; Antibiotics, Antineoplastic; Diterpenes; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; Leukemia P388; Mice | 1991 |
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Topics: Amsacrine; Animals; Antineoplastic Agents; Camptothecin; Cricetinae; Daunorubicin; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Humans; Mice; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1991 |
Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Division; Cell Line; Cell Survival; DNA; DNA Damage; Etoposide; Humans; Teniposide; Topoisomerase II Inhibitors | 1991 |
Acute megakaryoblastic leukemia: a case report.
Topics: Acid Phosphatase; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Etoposide; Humans; Leukemia, Megakaryoblastic, Acute; Male; Neoplasm Proteins; Neoplastic Stem Cells; Primary Myelofibrosis | 1990 |
Acute megakaryoblastic leukemia associated with mosaic Down's syndrome.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 17; Clone Cells; Cyclophosphamide; Cytarabine; Down Syndrome; Doxorubicin; Etoposide; Female; Humans; Hydrocortisone; Infant; Leukemia, Megakaryoblastic, Acute; Methotrexate; Mosaicism; Prednisone; Thioguanine; Trisomy | 1987 |
Chemotherapy of malignant disease: an update.
Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male; Mitoxantrone; Neoplasms; Pentostatin; Pregnancy | 1988 |
Pharmacokinetics of anticancer drugs in children.
Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Child; Cyclophosphamide; Etoposide; Humans; Kinetics; Mercaptopurine; Methotrexate; Naphthacenes; Podophyllotoxin; Teniposide; Vinca Alkaloids | 1983 |
Treatment of acute leukemia--advances in chemotherapy, immunotherapy, and bone marrow transplantation.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aminoacridines; Amsacrine; Anthraquinones; Antibodies, Monoclonal; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Immunotherapy; Infant; Interferons; Leukemia; Leukemia, Lymphoid; Liposomes; Middle Aged; Mitoxantrone; Naphthacenes; Prognosis; Teniposide; Transplantation, Homologous; Transplantation, Isogeneic; Vinblastine; Vindesine | 1983 |
Toxic megacolon complicating chemotherapy for acute myeloid leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Megacolon, Toxic | 1994 |
Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Genistein; Humans; Isoflavones; Models, Structural; Quinolones; Topoisomerase II Inhibitors | 1994 |
Using yeast to study resistance to topoisomerase II-targeting drugs.
Topics: Amsacrine; Animals; Drug Design; Drug Resistance, Microbial; Etoposide; Gene Expression; Genes, Fungal; Phenotype; Saccharomyces cerevisiae; Topoisomerase II Inhibitors | 1994 |
Schedule-dependent topoisomerase II-inhibiting drugs.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Cycle; Clinical Trials, Phase I as Topic; DNA Repair; Drug Administration Schedule; Etoposide; Humans; Metabolic Clearance Rate; Neoplasms; Teniposide; Topoisomerase II Inhibitors | 1994 |
DNA topoisomerase II mutations and resistance to anti-tumor drugs.
Topics: Amsacrine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Cricetinae; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Humans; Mice; Mutation; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Saccharomyces cerevisiae; Sequence Deletion; Substrate Specificity; Topoisomerase II Inhibitors | 1995 |
DNA topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Etoposide; Evidence-Based Medicine; Humans; Intestinal Absorption; Mitoxantrone; Neoplasms; Nucleic Acid Synthesis Inhibitors; Research Design; Risk Factors; Teniposide; Tissue Distribution; Topoisomerase II Inhibitors | 2000 |
42 trial(s) available for amsacrine and etoposide
| Article | Year |
|---|---|
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
[Effects of alternating as well as long-term intensive polychemotherapy in the remission-maintaining treatment of patients with acute myelocytic leukemia].
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thioguanine; Time Factors | 1992 |
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Daunorubicin; Doxorubicin; Drug Combinations; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Nimustine; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Thioguanine; United Kingdom; Vincristine | 1990 |
Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.
Topics: Adolescent; Amsacrine; Ancitabine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Pediatrics; Remission Induction | 1991 |
Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Pilot Projects | 1991 |
[Autotransplantation in acute nonlymphoid leukemia].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Prognosis; Survival Analysis | 1991 |
BAVC regimen in CR AML patients.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Etoposide; Follow-Up Studies; Graft Survival; Humans; Infant; Italy; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Survival Rate; Transplantation, Autologous | 1991 |
Acute myeloid leukaemia: results of the New Zealand AML-1 study. The Leukaemia Study Group of the New Zealand Society for Haematology.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; New Zealand; Remission Induction; Survival Rate | 1991 |
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Denmark; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Regression Analysis; Remission Induction; Survival Rate | 1991 |
Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Pilot Projects; Proportional Hazards Models; Remission Induction | 1991 |
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Random Allocation; Remission Induction; Risk; Thioguanine; United Kingdom | 1987 |
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Combinations; England; Etoposide; Humans; Leukemia, Myeloid, Acute; Prednisone; Remission Induction; Thioguanine; Vincristine | 1987 |
Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Prednisolone; Thioguanine; Vincristine | 1987 |
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Leukemia, Myeloid, Acute; Mitoguazone; Recurrence | 1981 |
High-dose Ara-C for remission induction and consolidation of previously untreated adults with ALL or lymphoblastic lymphoma.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Male; Methotrexate; Middle Aged; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Remission Induction; Survival Rate; Time Factors; Vincristine | 1995 |
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction | 1994 |
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local | 1996 |
BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 1996 |
Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Life Tables; Male; Middle Aged; Recurrence; Risk; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group.
Topics: Adolescent; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Mitoxantrone; Netherlands; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Treatment Outcome | 1997 |
Outcome of a multicenter treatment program including autologous or allogeneic bone marrow transplantation for de novo acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cause of Death; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Mitoxantrone; Probability; Remission Induction; Survival Rate; Transplantation, Autologous; Transplantation, Homologous | 1997 |
Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Amsacrine; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis; Warfarin | 1997 |
Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Male; Mitoxantrone; Patient Compliance; Recurrence; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 1998 |
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Vincristine | 1998 |
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis | 1998 |
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study.
Topics: Adult; Aged; Amsacrine; Chromatography, High Pressure Liquid; Cytarabine; Drug Administration Schedule; Etoposide; Female; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neutropenia; Time Factors | 1998 |
Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucémies Aigues Myeloblastiques.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hospitalization; Humans; Length of Stay; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neutropenia; Recombinant Proteins; Remission Induction; Treatment Outcome | 2000 |
Analysis of messy longitudinal data from a randomized clinical trial. MRC Lung Cancer Working Party.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cytarabine; Data Interpretation, Statistical; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Models, Statistical; Quality of Life; Randomized Controlled Trials as Topic; Time Factors | 2000 |
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Aminoglycosides; Amsacrine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Cohort Studies; Cytarabine; Doxorubicin; Etoposide; Feasibility Studies; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Pilot Projects; Remission Induction; Thioguanine; Vidarabine | 2003 |
More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Caspase 14; Caspases; Cohort Studies; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Idarubicin; Leukapheresis; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Transplantation, Autologous | 2003 |
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Idarubicin; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Prospective Studies; Remission Induction; Risk Assessment; Stem Cell Transplantation; Survival Analysis | 2004 |
Rescue therapy combining intermediate-dose cytarabine with amsacrine and etoposide in relapsed adult acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2004 |
Induction chemotherapy for acute myelogenous leukemia.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Cytarabine; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Remission Induction; Salvage Therapy; Transplantation, Autologous | 2005 |
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diarrhea; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Nausea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome; Vomiting, Anticipatory | 2005 |
Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Down Syndrome; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid; Leukocyte Count; Male; Mitoxantrone; Thioguanine; Treatment Outcome; United Kingdom | 2006 |
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Etoposide; Feasibility Studies; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Lenograstim; Leukemia, Myeloid; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Recombinant Proteins; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Citrulline as a marker for chemotherapy induced mucosal barrier injury in pediatric patients.
Topics: Acute Disease; Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carbohydrates; Cell Death; Child; Child, Preschool; Citrulline; Cytarabine; Daunorubicin; DNA; Enterocytes; Etoposide; Feces; Female; Humans; Infant; Interleukin-8; Intestinal Absorption; Leukemia, Myeloid; Leukocyte L1 Antigen Complex; Male; Mitoxantrone; Models, Biological; Mucositis; Stomatitis | 2009 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
247 other study(ies) available for amsacrine and etoposide
| Article | Year |
|---|---|
Topoisomerase II-mediated DNA cleavage by adocia- and xestoquinones from the Philippine sponge Xestospongia sp.
Topics: Animals; Antineoplastic Agents; Crystallography, X-Ray; DNA; Drug Screening Assays, Antitumor; Humans; Intercalating Agents; Magnetic Resonance Spectroscopy; Molecular Structure; Philippines; Porifera; Quinones; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Inhibition of topoisomerase II catalytic activity by pyridoacridine alkaloids from a Cystodytes sp. ascidian: a mechanism for the apparent intercalator-induced inhibition of topoisomerase II.
Topics: Acridines; Alkaloids; Animals; Catalysis; Cell Survival; CHO Cells; Cricetinae; DNA; Humans; Intercalating Agents; Magnetic Resonance Spectroscopy; Pyridones; RNA; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urochordata | 1994 |
9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
Topics: Acridines; Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Half-Life; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Mammalian topoisomerase II inhibitory activity of 1-cyclopropyl-6,8- difluoro-1,4-dihydro-7-(2,6-dimethyl-4-pyridinyl)-4-oxo-3-quinolinecarb oxylic acid and related derivatives.
Topics: Animals; Anti-Infective Agents; Fluoroquinolones; HeLa Cells; Humans; Leukemia P388; Mice; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |
Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
Topics: Acridines; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Mice; Mice, Inbred C57BL; Models, Chemical; Phenazines; Quinolines; Quinoxalines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 1997 |
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
Topics: Acridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; Microscopy, Fluorescence; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Synthesis and cytotoxic activity of carboxamide derivatives of benzo[b][1,6]naphthyridines.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Screening Assays, Antitumor; Humans; Mice; Naphthyridines; Neoplasm Transplantation; Neoplasms, Experimental; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.
Topics: Adenosine Triphosphatases; Animals; Anti-Bacterial Agents; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding, Competitive; Calcium Channel Blockers; Cyclosporine; Detergents; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluoresceins; Humans; Ivermectin; Mice; NIH 3T3 Cells; Substrate Specificity | 2004 |
Analogs of the marine alkaloid makaluvamines: synthesis, topoisomerase II inhibition, and anticancer activity.
Topics: Alkaloids; Amsacrine; Animals; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Marine Biology; Molecular Structure; Pyrroles; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2007 |
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
Topics: Acetylcysteine; Antineoplastic Agents, Phytogenic; Antioxidants; Curcumin; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; K562 Cells; Microscopy, Fluorescence; Molecular Structure; Reactive Oxygen Species; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2007 |
Synthesis and antiproliferative activity of benzyl and phenethyl analogs of makaluvamines.
Topics: Benzene; Cell Line, Tumor; Cell Proliferation; Humans; Molecular Structure; Pyrroles; Quinolones; Quinones; Structure-Activity Relationship | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
3-(3-Butylamino-2-hydroxy-propoxy)-1-hydroxy-xanthen-9-one acts as a topoisomerase IIα catalytic inhibitor with low DNA damage.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Structure-Activity Relationship; Topoisomerase II Inhibitors; Xanthones | 2013 |
Novel N-4-piperazinyl-ciprofloxacin-chalcone hybrids: synthesis, physicochemical properties, anticancer and topoisomerase I and II inhibitory activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chalcone; Ciprofloxacin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Piperazines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2013 |
Synthesis and Mechanism Studies of 1,3-Benzoazolyl Substituted Pyrrolo[2,3-b]pyrazine Derivatives as Nonintercalative Topoisomerase II Catalytic Inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Catalysis; Cell Line, Tumor; Cell Proliferation; DNA; DNA Helicases; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Docking Simulation; Pyrazines; Pyrroles; Receptors, Purinergic P2; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2016 |
Synthesis and antiproliferative activity of 9-benzylamino-6-chloro-2-methoxy-acridine derivatives as potent DNA-binding ligands and topoisomerase II inhibitors.
Topics: Acridines; Antineoplastic Agents; Apoptosis; Biological Transport; Cell Division; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; DNA; DNA Damage; DNA Topoisomerases, Type II; Drug Design; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Humans; Ligands; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2016 |
Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Humans; Molecular Docking Simulation; Pyridines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2017 |
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Fluorescein; G1 Phase Cell Cycle Checkpoints; Humans; Hydrazones; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
Topics: Acridines; Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; DNA; DNA Cleavage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Activation; Humans; Intercalating Agents; Topoisomerase II Inhibitors | 2017 |
Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Biocatalysis; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and IIα dual inhibitors with DNA non-intercalative catalytic activity.
Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Halogenation; Humans; Neoplasms; Pyridines; Topoisomerase II Inhibitors | 2017 |
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Isoquinolines; Molecular Structure; Polymerization; Structure-Activity Relationship; Topoisomerase I Inhibitors; Tubulin | 2018 |
Neutral Porphyrin Derivative Exerts Anticancer Activity by Targeting Cellular Topoisomerase I (Top1) and Promotes Apoptotic Cell Death without Stabilizing Top1-DNA Cleavage Complexes.
Topics: Antineoplastic Agents; Apoptosis; Biocatalysis; DNA Breaks; DNA Cleavage; DNA Topoisomerases, Type I; Humans; MCF-7 Cells; Porphyrins; Reactive Oxygen Species; Topoisomerase I Inhibitors | 2018 |
Synthesis of carbazole derivatives containing chalcone analogs as non-intercalative topoisomerase II catalytic inhibitors and apoptosis inducers.
Topics: Antineoplastic Agents; Apoptosis; Biocatalysis; Carbazoles; Cell Cycle Checkpoints; Cell Proliferation; Chalcone; DNA Cleavage; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Molecular Structure; Plasmids; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Novel ciprofloxacin hybrids using biology oriented drug synthesis (BIODS) approach: Anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis, topoisomerase II inhibition, and antibacterial activity.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Bacillus subtilis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Escherichia coli; Humans; Microbial Sensitivity Tests; Molecular Structure; Pseudomonas aeruginosa; Staphylococcus aureus; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; HeLa Cells; Humans; Indenes; Molecular Structure; Phenols; Pyridones; Structure-Activity Relationship; Topoisomerase Inhibitors | 2018 |
Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type I; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Point Mutation; Topoisomerase I Inhibitors | 2019 |
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Proliferation; Cell Survival; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred ICR; Microwaves; Molecular Structure; Pyridines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2019 |
Design, synthesis and biological research of novel N-phenylbenzamide-4-methylamine acridine derivatives as potential topoisomerase I/II and apoptosis-inducing agents.
Topics: Apoptosis; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Methylamines; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2019 |
A new 1-nitro-9-aminoacridine derivative targeting yeast topoisomerase II able to overcome fluconazole-resistance.
Topics: Aminacrine; Antifungal Agents; Candida albicans; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Resistance, Fungal; Fluconazole; Molecular Structure; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2021 |
Irreversible inhibition of human cytomegalovirus replication by topoisomerase II inhibitor, etoposide: a new strategy for the treatment of human cytomegalovirus infection.
Topics: Amsacrine; Cell Division; Cell Line; Cell Survival; Cytomegalovirus; Cytomegalovirus Infections; DNA Damage; DNA Replication; DNA, Viral; Electrophoresis, Polyacrylamide Gel; Etoposide; Fibroblasts; Humans; Lung; Peptide Biosynthesis; Topoisomerase II Inhibitors; Virus Replication | 1992 |
Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
Topics: Amsacrine; Casein Kinase II; DNA; DNA Topoisomerases, Type II; Etoposide; Nucleic Acid Denaturation; Nucleic Acid Renaturation; Phosphorylation; Protein Kinase C; Protein Serine-Threonine Kinases | 1992 |
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
Topics: Amsacrine; Antineoplastic Agents; Cell Nucleus; Drug Resistance; Etoposide; Humans; In Vitro Techniques; Leukemia; Leukemia, Promyelocytic, Acute; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Differential effects of amsacrine and epipodophyllotoxins on topoisomerase II cleavage in the human c-myc protooncogene.
Topics: Amsacrine; Animals; Base Sequence; Binding Sites; Carcinoma, Small Cell; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Genes, myc; Humans; Leukemia L1210; Lung Neoplasms; Mice; Molecular Sequence Data; Promoter Regions, Genetic; Restriction Mapping; Substrate Specificity; Teniposide | 1992 |
Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
Topics: Amsacrine; DNA Topoisomerases, Type II; Etoposide; Gene Expression Regulation, Enzymologic; Genes, Fungal; Mutation; Plasmids; Saccharomyces cerevisiae | 1992 |
The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
Topics: Amsacrine; Aphidicolin; Cell Cycle; Cell Differentiation; Cycloheximide; Deoxyadenosines; Dose-Response Relationship, Drug; Etoposide; G2 Phase; Hemoglobins; Humans; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanins; Mitosis; Novobiocin; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Inhibitors of topoisomerases do not block the passage of human lymphocyte chromosomes through mitosis.
Topics: Amsacrine; Camptothecin; Chromosome Aberrations; Chromosomes, Human; Daunorubicin; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Ellipticines; Ethidium; Etoposide; Humans; In Vitro Techniques; Lymphocytes; Mitosis; Mitoxantrone; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Leukemia; Lung Neoplasms; Novobiocin; RNA; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Bone Marrow Transplantation; Cause of Death; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Middle Aged; Norway; Recurrence; Remission Induction; Survival Analysis; Survival Rate; Thioguanine | 1992 |
Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Arabinofuranosylcytosine Triphosphate; Cytarabine; Drug Interactions; Etoposide; Humans; Leukemia; Middle Aged; Neoplastic Stem Cells; Phosphorylation; Teniposide; Tumor Cells, Cultured | 1992 |
Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
Topics: Amsacrine; Blotting, Western; Cell Death; Cross-Linking Reagents; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; Humans; In Vitro Techniques; Male; Testicular Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1991 |
The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Topics: Alkaloids; Amsacrine; Cell Line; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Humans; Leukemia; Protein Kinase C; Staurosporine; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured | 1991 |
Comparison of in vitro activity of epipodophyllotoxins with other chemotherapeutic agents in human medulloblastomas.
Topics: Alkylating Agents; Amsacrine; Cell Division; Cell Survival; Cross-Linking Reagents; Cytarabine; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Hydroxyurea; In Vitro Techniques; Karyotyping; Medulloblastoma; Teniposide; Tumor Cells, Cultured; Vincristine | 1991 |
Use of anion-exchange chromatography and chromatofocusing to reveal the structural and functional heterogeneity of topoisomerase II in a HL-60 cell line resistant to multi-drug treatment.
Topics: Amsacrine; Catalysis; Cell Line; Chromatography, Ion Exchange; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Protein Conformation; Structure-Activity Relationship; Vanadates | 1991 |
Potentiation by phenylbisbenzimidazoles of cytotoxicity of anticancer drugs directed against topoisomerase II.
Topics: Acridines; Amsacrine; Animals; Antineoplastic Agents; Benzimidazoles; Bisbenzimidazole; Colonic Neoplasms; Doxorubicin; Drug Synergism; Etoposide; Fluorescent Dyes; Leukemia L1210; Lung Neoplasms; Melanoma; Mice; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1990 |
Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons.
Topics: Amsacrine; Animals; Antibiotics, Antineoplastic; Aphidicolin; Camptothecin; Cell Survival; Cricetinae; Cricetulus; Cycloheximide; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA; Etoposide; Mutagens; Nucleic Acids; RNA; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1990 |
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide; Daunorubicin; Deoxyadenosines; Dichlororibofuranosylbenzimidazole; Diterpenes; DNA Polymerase II; DNA Replication; Drug Synergism; Etoposide; Female; Humans; Leukemia, Promyelocytic, Acute; Mutagens; RNA; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1991 |
Reproductive death of Chinese hamster V79 cells after exposure to chemical inhibitors of DNA synthesis.
Topics: 4-Nitroquinoline-1-oxide; Amsacrine; Animals; Benzamides; Bisbenzimidazole; Cell Division; Cell Line; Cisplatin; Cricetinae; Cricetulus; Cycloheximide; DNA Replication; Etoposide; Gene Expression Regulation; In Vitro Techniques; Kinetics; Methylnitronitrosoguanidine; Puromycin; Teniposide; Transcription, Genetic; Uracil | 1991 |
Effects of antineoplastic drugs on the post-strand-passage DNA cleavage/religation equilibrium of topoisomerase II.
Topics: Adenylyl Imidodiphosphate; Amsacrine; Animals; DNA; DNA Topoisomerases, Type II; Drosophila melanogaster; Etoposide; Hydrolysis; Kinetics | 1991 |
Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes.
Topics: Amsacrine; Animals; Cycloheximide; Dactinomycin; Dexamethasone; DNA; Electrophoresis; Etoposide; Flow Cytometry; Lymphocytes; Mitosis; Rats; Rats, Inbred Strains; Teniposide; Thymus Gland; Time Factors; Topoisomerase II Inhibitors | 1991 |
A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance.
Topics: Amsacrine; Breast Neoplasms; Cell Line; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Female; Humans; Immunoblotting | 1991 |
Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA Topoisomerases, Type II; Drug Resistance; Drug Synergism; Etoposide; Leukemia P388; Mice; Mice, Inbred Strains; Mitoxantrone | 1991 |
Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression.
Topics: Amsacrine; Antigens, Differentiation; Cell Differentiation; Cell Division; Etoposide; Gene Expression Regulation, Leukemic; Humans; Leukemia, Monocytic, Acute; Novobiocin; Oxygen; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vimentin | 1991 |
[Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Life Tables; Male; Methotrexate; Mitoxantrone; Remission Induction; Survival Rate; Thioguanine; Transplantation, Autologous; Transplantation, Homologous | 1991 |
[Acute myeloblastic leukemia 5q-. Clinical and cytogenetic remission by means of intensive chemotherapy].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Megakaryoblastic, Acute; Male; Middle Aged; Mitoxantrone; Mosaicism; Remission Induction | 1991 |
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Small Cell; Cell Cycle; Cell Division; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Humans; Lung Neoplasms; Membrane Glycoproteins; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Verapamil | 1990 |
HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Catalase; Cell Line; Cell Nucleus; DNA Probes; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Fibrosarcoma; Glucosephosphate Dehydrogenase; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Humans; Kinetics; Membrane Glycoproteins; Neoplasm Proteins; Superoxide Dismutase; Topoisomerase II Inhibitors | 1990 |
Tests for the genotoxicity of m-AMSA, etoposide, teniposide and ellipticine in Neurospora crassa.
Topics: Alkaloids; Amsacrine; Ellipticines; Etoposide; Molecular Structure; Mutagenicity Tests; Mutagens; Neurospora crassa; Podophyllotoxin; Teniposide | 1990 |
Stimulation by gamma-carboline derivatives (simplified analogues of antitumor ellipticines) of site specific DNA cleavage by calf DNA topoisomerase II.
Topics: Amsacrine; Animals; Antineoplastic Agents; Base Sequence; Carbolines; Cattle; Deoxyribonucleases, Type II Site-Specific; DNA Restriction Enzymes; DNA Topoisomerases, Type II; DNA, Bacterial; Ellipticines; Etoposide; Molecular Sequence Data; Molecular Structure; Plasmids; Structure-Activity Relationship | 1990 |
Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol.
Topics: Amsacrine; Animals; Cattle; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Bacterial; Enzyme Inhibitors; Escherichia coli; Etoposide; Flavonoids; Genistein; Humans; Intercalating Agents; Isoflavones; Molecular Structure; Structure-Activity Relationship | 1990 |
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Topics: Aclarubicin; Amsacrine; Carcinoma, Small Cell; Cell Survival; DNA Damage; DNA, Neoplasm; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1990 |
DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Topics: Amsacrine; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Mutation; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1990 |
Embryotoxicity of the intercalating agents m-AMSA and o-AMSA and the epipodophyllotoxin VP-16 in postimplantation rat embryos in vitro.
Topics: Abnormalities, Drug-Induced; Amsacrine; Animals; Antineoplastic Agents; DNA Damage; DNA Topoisomerases, Type II; Embryo, Mammalian; Etoposide; In Vitro Techniques; Intercalating Agents; Rats; Topoisomerase II Inhibitors | 1990 |
Novobiocin inhibits the repair of potentially lethal damage but not the repair of sublethal damage.
Topics: Amsacrine; Animals; Cell Line; Cricetinae; DNA Damage; DNA Repair; Etoposide; Novobiocin; Teniposide; Topoisomerase II Inhibitors | 1990 |
DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.
Topics: Amsacrine; Animals; Cell Line; Cell Survival; Cricetinae; DNA; DNA Damage; DNA Repair; Drug Tolerance; Etoposide; Free Radicals; Proteins; Topoisomerase II Inhibitors | 1990 |
Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
Topics: Amsacrine; Cell Adhesion; Cell Differentiation; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Gene Expression; Humans; In Vitro Techniques; Leukemia, Myeloid; Molecular Weight; Nuclear Proteins; Phorbol Esters; Proto-Oncogene Proteins c-myc; RNA, Messenger; Tumor Cells, Cultured | 1990 |
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; France; Humans; Leukemia, Myeloid, Acute; Life Tables; Middle Aged; Neutropenia; Survival Rate | 1990 |
Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Topics: Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Combined Modality Therapy; Cytarabine; Etoposide; Humans; Leukemia; Mitoxantrone; Neoplasm Recurrence, Local | 1990 |
BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Analysis | 1990 |
Hypersensitivity of cultured ataxia-telangiectasia cells to etoposide.
Topics: Aminoacridines; Amsacrine; Ataxia Telangiectasia; Bleomycin; Cell Survival; Cells, Cultured; DNA; Etoposide; Fibroblasts; Humans; Podophyllotoxin | 1986 |
Novobiocin, nalidixic acid, etoposide, and 4'-(9-acridinylamino)methanesulfon-m-anisidide effects on G2 and mitotic Chinese hamster ovary cell progression.
Topics: Amsacrine; Animals; Cell Line; Cell Survival; DNA Damage; Etoposide; Interphase; Metaphase; Mitosis; Nalidixic Acid; Novobiocin; RNA; Topoisomerase II Inhibitors | 1989 |
Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Topics: Amsacrine; Animals; Cell Line; Cell Survival; Cricetinae; Cricetulus; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide | 1989 |
Relationship between topoisomerase II and radiosensitivity in mouse L5178Y lymphoma strains.
Topics: Amsacrine; Animals; Cells, Cultured; DNA Repair; DNA Topoisomerases, Type II; Ellipticines; Etoposide; Leukemia L5178; Leukemia, Experimental; Mice; Mutation; Radiation Tolerance; Species Specificity; Thymidine Kinase | 1989 |
Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line.
Topics: Amsacrine; Carcinoma, Squamous Cell; Cell Survival; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Head and Neck Neoplasms; Humans; Tretinoin; Tumor Cells, Cultured | 1989 |
Mitogen-induced topoisomerase II synthesis precedes DNA synthesis in human breast cancer cells.
Topics: Amsacrine; Blotting, Western; Breast Neoplasms; Cross-Linking Reagents; DNA; DNA Topoisomerases, Type II; DNA, Neoplasm; Estrogens; Etoposide; Humans; Tumor Cells, Cultured | 1989 |
Topoisomerase II: a potential target for novel antifungal agents.
Topics: Amiloride; Amsacrine; Antifungal Agents; DNA, Superhelical; Etoposide; Molecular Structure; Novobiocin; Plasmids; Podophyllotoxin; Saccharomyces cerevisiae; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1989 |
Isolation of two Chinese hamster ovary cell mutants hypersensitive to topoisomerase II inhibitors and cross-resistant to peroxides.
Topics: Amsacrine; Animals; Cell Line; Cell Survival; Cricetinae; Dactinomycin; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Female; Mitoxantrone; Mutation; Ovary; Teniposide; Topoisomerase II Inhibitors | 1989 |
Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
Topics: Adenosine Triphosphate; Amsacrine; Blotting, Northern; Blotting, Southern; Cell Line; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Kinetics; Leukemia, Promyelocytic, Acute; Tumor Cells, Cultured | 1989 |
Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Topics: Amsacrine; Animals; Aphidicolin; Camptothecin; Cell Line; Cell Survival; Cricetinae; Cricetulus; Diterpenes; DNA Replication; Etoposide; Hydroxyurea; Kinetics; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1989 |
Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Topics: Amsacrine; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type II; DNA, Viral; Doxorubicin; Drug Resistance; Etoposide; Leukemia L1210; Membrane Glycoproteins; Mice; Neoplasm Proteins; Phenotype; Simian virus 40; Tumor Cells, Cultured | 1989 |
Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Survival Rate | 1989 |
Further characterization of drug-sensitivity and cross-resistance profiles of cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia.
Topics: Amsacrine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Survival; Clone Cells; DNA Damage; Doxorubicin; Drug Resistance; Etoposide; Leukemia P388; Mice; Tumor Cells, Cultured; Vinblastine; Vincristine | 1989 |
Autologous bone marrow transplantation in patients with AML in second complete remission (CR).
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Etoposide; Evaluation Studies as Topic; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction; Transplantation, Autologous | 1989 |
Topoisomerase alterations associated with drug resistance in a line of Chinese hamster cells.
Topics: Alkaloids; Amsacrine; Animals; Antineoplastic Agents; Cell Line; Cricetinae; Cricetulus; DNA Topoisomerases, Type II; Drug Resistance; Ellipticines; Etoposide; Kinetics | 1987 |
Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.
Topics: Amsacrine; Animals; Cell Line; Cricetinae; Cricetulus; Daunorubicin; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Female; Mutation; Ovary | 1987 |
Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Topics: Alkynes; Amsacrine; Animals; Antineoplastic Agents; Cell Line; Cell Survival; Diamines; DNA; DNA Damage; DNA Topoisomerases, Type II; Eflornithine; Etoposide; Humans; Leukemia L1210; Leukemia, Myeloid, Acute; Mice; Ornithine Decarboxylase Inhibitors; Polyamines; Tumor Cells, Cultured | 1987 |
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human le
Topics: Amsacrine; Cell Division; Cell Nucleus; Cytarabine; DNA; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Leukemia; Tumor Cells, Cultured | 1987 |
Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Topics: Amsacrine; Breast Neoplasms; Cell Survival; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Doxorubicin; Drug Synergism; Estrogens; Etoposide; Female; Humans; Mitoxantrone; Tumor Cells, Cultured | 1988 |
Sister chromatid exchanges, chromosomal aberrations, and cytotoxicity produced by antitumor topoisomerase II inhibitors in sensitive (DC3F) and resistant (DC3F/9-OHE) Chinese hamster cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Line; Cell Survival; Chromosome Aberrations; Cricetinae; Drug Resistance; Ellipticines; Etoposide; Mitomycin; Mitomycins; Sister Chromatid Exchange; Topoisomerase II Inhibitors | 1988 |
Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
Topics: Adenosine Triphosphate; Amsacrine; Animals; Cross-Linking Reagents; DNA; DNA Damage; DNA Replication; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Leukemia L1210; Mice; Novobiocin; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors | 1988 |
Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
Topics: Amsacrine; DNA; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance; Etoposide; Flow Cytometry; Humans; Leukemia, Lymphoid; Lymphocytes | 1988 |
Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Topics: Amsacrine; Chromatin; DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Proto-Oncogenes; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1988 |
Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.
Topics: Aminoacridines; Amsacrine; Animals; Cell Line; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Female; Ovary; Podophyllotoxin | 1986 |
Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
Topics: Adenosine Triphosphate; Aminoacridines; Amsacrine; Animals; Cell Nucleus; Cells, Cultured; Centrifugation, Density Gradient; Cricetinae; Cricetulus; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Electrophoresis, Polyacrylamide Gel; Etoposide; Molecular Weight; Topoisomerase II Inhibitors | 1986 |
Proliferation dependence of topoisomerase II mediated drug action.
Topics: Aminoacridines; Amsacrine; Animals; Cell Line; Cricetinae; Cricetulus; DNA Replication; DNA Topoisomerases, Type II; Etoposide; Female; HeLa Cells; Humans; Intercalating Agents; Kinetics; Leukemia L1210; Mice; Ovary; Plasmids; Podophyllotoxin | 1986 |
Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.
Topics: Amsacrine; Animals; Carbazoles; Cross-Linking Reagents; DNA Damage; DNA, Neoplasm; Etoposide; Intercalating Agents; Leukemia L1210; Mice; Nucleic Acid Conformation; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1986 |
Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Topics: Amsacrine; Animals; Cell Cycle; Cell Division; Cell Line; Cell Survival; DNA Damage; DNA Topoisomerases, Type I; Etoposide; Fibroblasts; Leukemia L1210; Mice; Proteins | 1987 |
Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
Topics: Adult; Amsacrine; Blood Transfusion; Drug Therapy, Combination; Etoposide; Factor IX; Factor X; Factor X Deficiency; Humans; Hypoprothrombinemias; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Prothrombin; Prothrombin Time | 1988 |
Combined chemotherapy with m-amsacrine in high-risk patients with acute non-lymphocytic leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Follow-Up Studies; Humans; Leukemia; Middle Aged; Thioguanine | 1987 |
Sequential pilot studies of intensive postremission chemotherapy for acute nonlymphocytic leukemia.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Pilot Projects; Thioguanine | 1987 |
Autologous bone marrow transplantation for patients with acute myelogenous leukemia in complete remission.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Evaluation Studies as Topic; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Postoperative Complications; Remission Induction; Transplantation, Autologous | 1987 |
Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Resistance; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Platelet Count | 1986 |
m-AMSA and VP-16 combinations in the treatment of acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Leukemia, Myeloid, Acute | 1987 |
Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction; Time Factors | 1987 |
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lung; Lymphoma, Non-Hodgkin; Prednisone; Radiography; Remission Induction; Respiratory Insufficiency | 1987 |
Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with L-asparaginase and amsacrine with etoposide.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Drug Evaluation; Etoposide; Humans; Leukemia; Middle Aged; Remission Induction; Statistics as Topic | 1987 |
Divergent patterns of resistance to etoposide and amsacrine.
Topics: Amsacrine; Animals; Cell Line; Cell Survival; DNA Damage; Drug Resistance; Etoposide; Mutation | 1986 |
Phase II study of combination chemotherapy with etoposide and amsacrine in relapsed adult leukemia.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bone Marrow; Drug Evaluation; Etoposide; Humans; Leukemia; Middle Aged | 1986 |
[A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Anthraquinones; Antineoplastic Agents; Cytarabine; Drug Administration Schedule; Etoposide; Humans; Leukemia; Mitoxantrone | 1986 |
Drug sensitivity and cross-resistance of the 4'-(9-acridinylamino)methanesulfon-m-anisidide-resistant subline of HL-60 human leukemia.
Topics: Aminoacridines; Amsacrine; Cell Line; Cell Survival; Cytarabine; Doxorubicin; Drug Resistance; Etoposide; Humans; Leukemia | 1986 |
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Cells, Cultured; DNA; DNA Repair; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide | 1985 |
Phase I study of VP-16 (etoposide) and amsacrine (AMSA) in the treatment of refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Evaluation; Drug Resistance; Etoposide; Female; Humans; Leukemia; Liver Function Tests; Male; Middle Aged | 1985 |
Amsacrine and etoposide induced paralytic ileus in a patient with acute myelomonocytic leukemia.
Topics: Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Podophyllotoxin | 1985 |
Malignant histiocytosis resistant to anthracycline. Response to intensive treatment with etoposide and amsacrine.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Doxorubicin; Drug Resistance; Etoposide; Female; Hepatomegaly; Humans; Leucovorin; Leukocyte Count; Lymphatic Diseases; Methotrexate; Prednisone; Splenomegaly; Vincristine | 1985 |
[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
Topics: Aminoacridines; Aminoglutethimide; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Danazol; Drug Evaluation; Drug Resistance; Etoposide; Humans; Leukemia, Myeloid, Acute; Tamoxifen | 1985 |
[Research project of cancer chemotherapy].
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Cisplatin; Dacarbazine; Etoposide; Humans; International Cooperation; Japan; Neoplasms; Research; Thioguanine; United States | 1985 |
[Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Etoposide; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute | 1984 |
Pilot studies of various combinations of dibromodulcitol, VP-16, and AMSA.
Topics: Aged; Aminoacridines; Amsacrine; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Middle Aged; Mitolactol; Neoplasms; Pilot Projects; Podophyllotoxin | 1982 |
[Prospects of new chemotherapies].
Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Male; Neoplasms; Podophyllotoxin; Vinblastine; Vindesine | 1982 |
Hyperthermia, thermotolerance and topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Combined Modality Therapy; DNA Damage; DNA, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Heat-Shock Proteins; Heating; HeLa Cells; Humans; Hyperthermia, Induced; Topoisomerase II Inhibitors | 1995 |
Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Topics: Amsacrine; Anti-Infective Agents; Base Sequence; DNA; DNA Topoisomerases, Type II; Etoposide; Fluoroquinolones; Humans; Hydrolysis; Molecular Sequence Data; Quinolones; Teniposide; Topoisomerase II Inhibitors | 1995 |
Micronuclei in neonatal lymphocytes treated with the topoisomerase II inhibitors amsacrine and etoposide.
Topics: Amsacrine; Cells, Cultured; Etoposide; Humans; Immunologic Techniques; Infant, Newborn; Micronucleus Tests; Topoisomerase II Inhibitors | 1993 |
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Topics: Amsacrine; Animals; Camptothecin; Cell Nucleus; Cricetinae; Cricetulus; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Resistance; Etoposide; Fibrosarcoma; Lung Neoplasms; Neoplasm Proteins; Suramin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Different topoisomerase II antitumor drugs direct similar specific long-range fragmentation of an amplified c-MYC gene locus in living cells and in high-salt-extracted nuclei.
Topics: Amsacrine; Antineoplastic Agents; Carcinoma, Small Cell; Cell Fractionation; Cell Line; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Exons; Genes, myc; Humans; Lung Neoplasms; Restriction Mapping; Saline Solution, Hypertonic; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
Topics: Amsacrine; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance, Multiple; Etoposide; Humans; Lung Neoplasms; Methylation; RNA, Messenger; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1995 |
An etoposide-induced block in vaccinia virus telomere resolution is dependent on the virus-encoded DNA ligase.
Topics: Amino Acid Sequence; Amsacrine; Animals; Base Sequence; Cells, Cultured; Chlorocebus aethiops; DNA Ligases; DNA Replication; DNA, Viral; Drug Resistance; Etoposide; Gene Expression; Molecular Sequence Data; Mutation; Telomere; Thymidine Kinase; Vaccinia virus; Virus Replication | 1995 |
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Daunorubicin; DNA Damage; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Membrane Glycoproteins; Molecular Weight | 1994 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluoresceins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1994 |
Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Topics: Amino Acid Sequence; Amsacrine; Base Sequence; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Glycine; Lysine; Molecular Sequence Data; Mutation; Oligodeoxyribonucleotides; Saccharomyces cerevisiae | 1994 |
Drug-sensitivity and DNA-binding of a subform of topoisomerase II alpha in resistant human HL-60 cells.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Isoenzymes; Leukemia; Tumor Cells, Cultured; Vanadates | 1994 |
Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; DNA Probes; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Humans; Immunoblotting; Leukemia; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured | 1994 |
Protection from adriamycin cytotoxicity in L1210 cells by brefeldin A.
Topics: Amsacrine; Animals; Biological Transport; Brefeldin A; Cell Survival; Cyclopentanes; DNA Damage; DNA Repair; Doxorubicin; Drug Synergism; Endoplasmic Reticulum; Etoposide; Golgi Apparatus; Kinetics; Leukemia L1210; Mice; Microtubules; Nocodazole; Paclitaxel; Temperature; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1993 |
Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.
Topics: Amsacrine; Antineoplastic Agents; Camptothecin; Carbazoles; Cell Cycle; Colonic Neoplasms; Diterpenes; DNA Replication; Dose-Response Relationship, Drug; Etoposide; Flow Cytometry; G2 Phase; Humans; Indoles; Mitosis; Quinones; S Phase; Teniposide; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Topics: Amino Acid Sequence; Amsacrine; Base Sequence; DNA Topoisomerases, Type II; DNA, Fungal; Drug Resistance; Etoposide; Molecular Sequence Data; Mutation; Sequence Analysis, DNA; Yeasts | 1994 |
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Topics: Amsacrine; Animals; Carcinoma, Small Cell; Chloroquine; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Hydrogen-Ion Concentration; Leukemia L1210; Lung Neoplasms; Mice; Tumor Cells, Cultured | 1994 |
Caffeine attenuates the action of amsacrine and etoposide in U-937 cells by mechanisms which involve inhibition of RNA synthesis.
Topics: Amsacrine; Caffeine; Cell Differentiation; Cell Division; Chromatin; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Humans; In Vitro Techniques; Neoplasm Proteins; RNA, Neoplasm; Tumor Cells, Cultured | 1994 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
Analysis of the DNA topoisomerase-II-mediated cleavage of the long terminal repeat of Drosophila 1731 retrotransposon.
Topics: Amsacrine; Animals; Base Sequence; DNA; DNA Topoisomerases, Type II; DNA Transposable Elements; Drosophila; Ellipticines; Etoposide; Molecular Sequence Data; Repetitive Sequences, Nucleic Acid | 1993 |
A drug-resistant variant of topoisomerase II alpha in human HL-60 cells exhibits alterations in catalytic pH optimum, DNA binding and sub-nuclear distribution.
Topics: Amsacrine; Animals; Catalysis; Cattle; Cell Nucleus; DNA; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Hydrogen-Ion Concentration; Protein Binding; Tumor Cells, Cultured | 1993 |
Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells.
Topics: Adult; Alkenes; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Drug Screening Assays, Antitumor; Etoposide; Hematopoietic Stem Cells; Humans; Polyenes; Pyrones; Thiobarbiturates; Topoisomerase II Inhibitors | 1994 |
Hepatic candidiasis: persistent pyrexia in a patient with acute myeloid leukaemia after recovery from consolidation therapy-induced neutropenia.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Candidiasis; Cytosine; Etoposide; Fever; Fluconazole; Focal Infection; Humans; Leukemia, Myelomonocytic, Acute; Liver Diseases; Male; Neutropenia; Remission Induction; Tomography, X-Ray Computed | 1993 |
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; In Vitro Techniques; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Pilot Projects; Prospective Studies; Recurrence; Salvage Therapy; Tumor Stem Cell Assay | 1993 |
A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Topics: Alleles; Amsacrine; Camptothecin; Cell Division; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Models, Biological; Saccharomyces cerevisiae; Sensitivity and Specificity; Temperature; Topoisomerase II Inhibitors | 1993 |
Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.
Topics: Amsacrine; Apoptosis; Camptothecin; Cell Differentiation; DNA; DNA Damage; Etoposide; Humans; Leukemia, Promyelocytic, Acute; Tetradecanoylphorbol Acetate; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured | 1993 |
Topoisomerase II function detected as protein-DNA complexes in two sublines of HL-60 cells.
Topics: Amsacrine; Antineoplastic Agents; Cell Survival; Dimethyl Sulfoxide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Etoposide; Humans; Nitroblue Tetrazolium; Tretinoin; Tumor Cells, Cultured | 1993 |
Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
Topics: Amsacrine; Antineoplastic Agents; Cell Differentiation; Cell Nucleus; DNA; Etoposide; Hematopoietic Stem Cells; Humans; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Topics: Adenosine Triphosphate; Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; Cell Nucleus; DNA Topoisomerases, Type II; DNA, Bacterial; Drosophila melanogaster; Escherichia coli; Etoposide; Fluoroquinolones; Genistein; Hydrolysis; Isoflavones; Novobiocin; Plasmids; Quercetin; Quinolones; Topoisomerase II Inhibitors | 1993 |
Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction.
Topics: Amsacrine; Antineoplastic Agents; Antiviral Agents; Base Sequence; Camptothecin; Carbazoles; DNA Nucleotidyltransferases; Ellipticines; Escherichia coli; Etoposide; HIV Long Terminal Repeat; HIV-1; Integrases; Kinetics; Molecular Sequence Data; Netropsin; Oligodeoxyribonucleotides; Plasmids; Recombinant Proteins; Substrate Specificity; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1993 |
Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Topics: Amsacrine; Animals; Anti-Infective Agents; Binding Sites; Cell Line; Cell Nucleus; DNA; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Drug Interactions; Etoposide; Fluoroquinolones; Genistein; Growth Inhibitors; Isoflavones; Kinetics; Novobiocin; Protein Binding; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Topics: Amsacrine; Camptothecin; Cell Survival; Chemical Precipitation; DNA Damage; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Humans; Male; Prostatic Neoplasms; Suramin; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cells.
Topics: Adenosine Triphosphate; Allosteric Site; Amsacrine; Chromatography, Ion Exchange; Clone Cells; DNA Topoisomerases, Type II; Drug Resistance; Etoposide; Humans; Isoenzymes; Leukemia, Promyelocytic, Acute; Molecular Weight; Neoplasm Proteins; Neoplastic Stem Cells; Point Mutation; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vanadates | 1993 |
The top2-5 mutant of yeast topoisomerase II encodes an enzyme resistant to etoposide and amsacrine.
Topics: Alleles; Amino Acid Sequence; Amsacrine; Antineoplastic Agents; Base Sequence; Cloning, Molecular; DNA Topoisomerases, Type II; DNA, Fungal; Drug Resistance, Microbial; Etoposide; Kinetics; Molecular Sequence Data; Mutation; Saccharomyces cerevisiae; Temperature; Topoisomerase II Inhibitors | 1993 |
Effect of ionizing radiation and topoisomerase II inhibitors on DNA synthesis in mammalian cells.
Topics: Amsacrine; Animals; Carcinoma, Ehrlich Tumor; DNA; DNA Repair; DNA Replication; DNA, Mitochondrial; Etoposide; Gamma Rays; Leukemia, Erythroblastic, Acute; Mice; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Topics: Amsacrine; Animals; Camptothecin; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA, Superhelical; Etoposide; Leukemia L5178; Mice; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma.
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Glucocorticoids; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Methotrexate; Prednisone; Prospective Studies; Vincristine; Virus Activation | 1996 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Finland; Humans; Immunocompromised Host; Incidence; Leukemia; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Pneumonia, Pneumocystis; Prednisone; Premedication; Retrospective Studies; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1996 |
Effect of transfection of a Drosophila topoisomerase II gene into a human brain tumour cell line intrinsically resistant to etoposide.
Topics: Amsacrine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Cell Cycle; Cell Line; Cell Survival; Cisplatin; Dexamethasone; DNA Topoisomerases, Type I; Doxorubicin; Drosophila; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Genetic Vectors; Humans; Kinetics; Mammary Tumor Virus, Mouse; Mice; Recombinant Proteins; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1996 |
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Kidney Failure, Chronic; Leukemia, Myeloid, Acute; Mitoxantrone | 1996 |
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Central Nervous System Neoplasms; DNA Topoisomerases, Type II; Etoposide; Female; Injections, Intraperitoneal; Lethal Dose 50; Leukemia L1210; Male; Mice; Mice, Inbred DBA; Paclitaxel; Razoxane; Structure-Activity Relationship | 1996 |
The distribution of topoisomerase II on mammalian chromosomes.
Topics: Amsacrine; Animals; Cells, Cultured; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Etoposide; Fibroblasts; Fluorescent Antibody Technique; Humans; L Cells; Lymphocytes; Mice; Mitosis; Mitoxantrone; Muridae; Rats; Topoisomerase II Inhibitors | 1996 |
Sister-chromatid exchanges (SCE) induction by inhibitors of DNA topoisomerases in cultured human lymphocytes.
Topics: Amsacrine; Camptothecin; Cells, Cultured; Enzyme Inhibitors; Etoposide; Humans; Lymphocytes; Mitomycin; Nalidixic Acid; Sister Chromatid Exchange; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1996 |
In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antigens, CD34; Antineoplastic Agents; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Recurrence; Risk Factors; Treatment Outcome | 1996 |
Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Topics: Amsacrine; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cycle; Cell Death; Cell Division; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Isoenzymes; Mice; RNA, Messenger; Transfection; Tumor Cells, Cultured | 1996 |
Induction of apoptotic cell death by DNA topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carmustine; Cell Survival; Cyclophosphamide; DNA Damage; DNA Topoisomerases, Type II; Etoposide; HeLa Cells; Humans; Intercalating Agents; Suramin; Topoisomerase II Inhibitors | 1995 |
Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Death; DNA; DNA Damage; DNA Replication; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Etoposide; G1 Phase; Mating Factor; Peptides; S Phase; Saccharomyces cerevisiae | 1996 |
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Mice; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan | 1996 |
DNA topoisomerase II inhibitors enhance random integration of transfected vectors into human chromosomes.
Topics: Amsacrine; Cell Line; Chromosomes, Human; Diketopiperazines; DNA Damage; Enzyme Inhibitors; Etoposide; Genetic Vectors; HeLa Cells; Humans; Kinetics; Piperazines; Plasmids; Recombination, Genetic; Topoisomerase II Inhibitors; Transfection | 1996 |
Effect of apoptosis-related compounds on Ca2+ transport system in isolated rat liver nuclei.
Topics: Amsacrine; Animals; Apoptosis; Aurintricarboxylic Acid; Biological Transport, Active; Calcium; Cell Nucleus; DNA Fragmentation; Etoposide; Genistein; Isoflavones; Male; Rats; Rats, Wistar | 1997 |
Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Topics: Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; CHO Cells; Ciprofloxacin; Cricetinae; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Electrophoresis, Agar Gel; Enzyme Activation; Etoposide; Fluoroquinolones; Genistein; Isoflavones; Kinetics; Molecular Structure; Quinolones | 1997 |
Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus.
Topics: Amsacrine; Antineoplastic Agents; Base Sequence; Cell Line; Dactinomycin; DNA Damage; DNA, Neoplasm; Doxorubicin; Etoposide; Genes, abl; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Monocytes; Restriction Mapping; Topoisomerase II Inhibitors; Translocation, Genetic | 1997 |
Sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous stem cell transplantation for primary systemic CD30 (Ki-1)--positive anaplastic large cell lymphoma in adults.
Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large-Cell, Anaplastic; Male; Methotrexate; Middle Aged; Prednisone; Prognosis; Prospective Studies; Remission Induction; Transplantation Conditioning; Transplantation, Autologous; Vincristine | 1997 |
Blast crisis of chronic myelogenous leukemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Blast Crisis; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Humans; Idarubicin; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Methotrexate; Prednisone; Remission Induction; Transplantation, Autologous; Vincristine | 1997 |
Inhibition of DNA unwinding and ATPase activities of human DNA helicase II by chemotherapeutic agents.
Topics: Adenosine Triphosphatases; Amsacrine; Antineoplastic Agents; Aphidicolin; Camptothecin; Dactinomycin; Daunorubicin; DNA; DNA Helicases; Ellipticines; Enzyme Inhibitors; Ethidium; Etoposide; Genistein; Humans; Isoflavones; Nogalamycin; Novobiocin; Topoisomerase I Inhibitors | 1997 |
Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.
Topics: Amsacrine; Animals; Cell Line; Codon; Cricetinae; Cricetulus; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Ellipticines; Enzyme Inhibitors; Etoposide; Fibroblasts; Genistein; Isoenzymes; Lung; Topoisomerase II Inhibitors | 1997 |
[Expression of ATP binding cassette superfamily (multidrug resistance-1, multidrug resistance-associated protein, human canalicular multispecific organ anion transporter) mRNA in etoposide and m-AMSA resistant cell lines].
Topics: Amsacrine; Anion Transport Proteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Blotting, Northern; Carrier Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Multidrug Resistance-Associated Proteins; Organoplatinum Compounds; RNA, Messenger; Tumor Cells, Cultured | 1997 |
[Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Northern; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Humans; Isoenzymes; Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 1997 |
Induction of chromosomal aberrations (unstable and stable) by inhibitors of topoisomerase II, m-AMSA and VP16, using conventional Giemsa staining and chromosome painting techniques.
Topics: Amsacrine; Azure Stains; Chromosome Aberrations; Chromosome Banding; Etoposide; Humans; Male; Staining and Labeling; Topoisomerase II Inhibitors; Translocation, Genetic | 1998 |
Inhibition of pea chloroplast DNA helicase unwinding and ATPase activities by DNA-interacting ligands.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Amsacrine; Camptothecin; Chloroplasts; Dactinomycin; Daunorubicin; DNA Helicases; Ellipticines; Ethidium; Etoposide; Genistein; Hydrolysis; Intercalating Agents; Ligands; Nogalamycin; Novobiocin; Pisum sativum | 1998 |
Improved targeting of brain tumors using dexrazoxane rescue of topoisomerase II combined with supralethal doses of etoposide and teniposide.
Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Administration Schedule; Etoposide; Female; Mice; Mice, Inbred Strains; Razoxane; Survival Rate; Teniposide; Topoisomerase II Inhibitors | 1998 |
Genotoxic activity of four inhibitors of DNA topoisomerases in larval cells of Drosophila melanogaster as measured in the wing spot assay.
Topics: Amsacrine; Animals; Camptothecin; Drosophila melanogaster; Etoposide; Larva; Mutagens; Nalidixic Acid; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1998 |
Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
Topics: Amsacrine; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cycloheximide; Dactinomycin; DNA Damage; DNA Topoisomerases, Type I; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Insulin-Like Growth Factor Binding Protein 3; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retinal Neoplasms; Retinoblastoma; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
[Incidence of mutation and deletion in topoisomerase II mRNA of etoposide and m-AMSA resistant cell lines].
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Gene Deletion; Humans; Mutation; Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 1998 |
Impact of exogenous growth factors on proliferation and chemosensitivity of minimal residual acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Ki-67 Antigen; Leukemia, Myeloid; Middle Aged; Neoplasm, Residual; Remission Induction; Tumor Stem Cell Assay | 1998 |
Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Butyrates; Butyric Acid; Camptothecin; Carboplatin; Cisplatin; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Paclitaxel; Retinoblastoma; Suramin; Tumor Cells, Cultured | 1998 |
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
Topics: Amsacrine; Bleomycin; Breast Neoplasms; Cell Division; Cell Survival; Cyclic AMP-Dependent Protein Kinase Type II; Cyclic AMP-Dependent Protein Kinases; DNA Topoisomerases, Type II; Etoposide; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Recombinant Proteins; Teniposide; Topoisomerase II Inhibitors; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 1995 |
Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cytarabine; Etoposide; Female; Humans; Infant; Infusions, Intravenous; Leukemia, Myeloid; Male; Mitoxantrone; Recurrence; Remission Induction | 1998 |
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL.
Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Hemorrhage; Humans; Idarubicin; Leukemia, Myeloid; Middle Aged; Mitoxantrone; Pancytopenia; Platelet Count; Platelet Transfusion; Retrospective Studies; Spain; Thrombocytopenia | 1998 |
Increased cyclin E level in retinoblastoma cells during programmed cell death.
Topics: Amsacrine; Apoptosis; Camptothecin; Cyclin A; Cyclin E; Enzyme Inhibitors; Etoposide; Humans; Interleukin-1; Retinoblastoma; Sphingosine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1998 |
Induction of diplochromosomes in mammalian cells by inhibitors of topoisomerase II.
Topics: Amsacrine; Animals; CHO Cells; Chromatids; Chromosome Aberrations; Chromosome Segregation; Cricetinae; Demecolcine; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Interphase; Metaphase; Mitoxantrone; Nucleic Acid Synthesis Inhibitors; Topoisomerase II Inhibitors | 1998 |
Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Topics: Adenosine Triphosphate; Amsacrine; Antineoplastic Agents; DNA Adducts; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
Inhibition of DNA topoisomerase II catalytic activity by the antiviral agents 7-chloro-1,3-dihydroxyacridone and 1,3,7-trihydroxyacridone.
Topics: Acridines; Amsacrine; Antineoplastic Agents; Antiviral Agents; Catalysis; DNA; Enzyme Inhibitors; Etoposide; Humans; Plasmids; Topoisomerase II Inhibitors | 1999 |
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Amino Acid Substitution; Amsacrine; Animals; Antineoplastic Agents; Binding Sites; Carcinoma, Small Cell; Catalysis; CHO Cells; Consensus Sequence; Cricetinae; Cricetulus; DNA Damage; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA, Neoplasm; DNA, Single-Stranded; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Lung Neoplasms; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Protein Isoforms; Razoxane; Recombinant Fusion Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Thiobarbiturates; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 1999 |
Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Topics: Acridines; Amsacrine; Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Cycle; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Humans; Isoenzymes; Mice; Poly-ADP-Ribose Binding Proteins; Saccharomyces cerevisiae; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1999 |
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxorubicin; Drug Screening Assays, Antitumor; Erythrocytes; Etoposide; Humans; Leukemia, Myeloid, Acute; Recurrence; Scandinavian and Nordic Countries; Thioguanine | 1999 |
Autologous bone marrow transplantation in non-Hodgkin's lymphoma patients: effect of a brief course of G-CSF on harvest and recovery.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Topics: Amsacrine; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cell Line; Cell Nucleus; Cell Survival; Cricetinae; Cricetulus; DNA Probes; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Complementary; DNA, Kinetoplast; Drug Resistance; Ellipticines; Etoposide; Fibroblasts; Humans; Isoenzymes; Phenotype; Point Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Recombinant Proteins; Transcription, Genetic; Transfection | 1999 |
Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Topics: Acridines; Amsacrine; Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Survival; Cells, Cultured; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Isoenzymes; Mice; Mice, Transgenic; Mitoxantrone; Topoisomerase II Inhibitors | 1999 |
Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposide.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Cell Cycle; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Isoenzymes; Phosphorylation | 1999 |
Werner's syndrome lymphoblastoid cells are hypersensitive to topoisomerase II inhibitors in the G2 phase of the cell cycle.
Topics: Amsacrine; Cell Line, Transformed; DNA Damage; DNA Helicases; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Exodeoxyribonucleases; G2 Phase; Humans; Nucleic Acid Synthesis Inhibitors; RecQ Helicases; Topoisomerase II Inhibitors; Werner Syndrome; Werner Syndrome Helicase | 2000 |
Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro.
Topics: Amsacrine; Animals; Antimalarials; Chloroquine; Drug Resistance, Multiple; Enzyme Inhibitors; Etoposide; Humans; Inhibitory Concentration 50; Malaria, Falciparum; Mefloquine; Naphthyridines; Norfloxacin; Nucleic Acid Synthesis Inhibitors; Plasmodium falciparum; Primaquine; Proguanil; Pyrimethamine; Thailand; Topoisomerase II Inhibitors; Triazines | 2000 |
Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Arginine; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Glutamic Acid; Humans; Isoenzymes; Point Mutation; Saccharomyces cerevisiae; Tumor Cells, Cultured | 2000 |
Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs.
Topics: Amsacrine; Animals; Antineoplastic Agents; Blood Proteins; Carcinoma, Lewis Lung; Cattle; Doxorubicin; Etoposide; Humans; Mice; Mitoxantrone; Orosomucoid; Protein Binding; Serum Albumin; Vincristine | 2000 |
Genotoxicity of several clinically used topoisomerase II inhibitors.
Topics: Amsacrine; Animals; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Mice; Micronuclei, Chromosome-Defective; Mutagens; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
N-terminal and core-domain random mutations in human topoisomerase II alpha conferring bisdioxopiperazine resistance.
Topics: Adenosine Triphosphate; Amsacrine; Antigens, Neoplasm; Diketopiperazines; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Mutagenesis; Nucleic Acid Synthesis Inhibitors; Piperazines; Razoxane; Topoisomerase II Inhibitors | 2000 |
Linkage of a triple helix-forming oligonucleotide to amsacrine-4-carboxamide derivatives modulates the sequence-selectivity of topoisomerase II-mediated DNA cleavage.
Topics: Amsacrine; Base Sequence; Binding Sites; Chromatography, Gel; DNA; DNA Footprinting; DNA Topoisomerases, Type II; Enzyme Inhibitors; Etoposide; Intercalating Agents; Molecular Sequence Data; Molecular Structure; Nucleic Acid Conformation; Nucleic Acid Denaturation; Oligodeoxyribonucleotides; Substrate Specificity; Topoisomerase II Inhibitors | 2000 |
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Apoptosis; bcl-X Protein; Chromatography, High Pressure Liquid; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Fusion Proteins, bcr-abl; Humans; K562 Cells; Leukemia; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.
Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Epirubicin; Etoposide; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization; Killer Cells, Natural; Lymphoma; Male; Methotrexate; Middle Aged; Nose Neoplasms; Prednisone; Radiotherapy; RNA, Viral; Treatment Outcome; Vincristine | 2001 |
Atp-bound topoisomerase ii as a target for antitumor drugs.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Amsacrine; Animals; Antineoplastic Agents; Cattle; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; Kinetics; Mitoxantrone; Mutagenesis, Site-Directed; Recombinant Proteins; Teniposide; Thymus Gland | 2001 |
Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration.
Topics: Acute Kidney Injury; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cytarabine; Etoposide; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2000 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution.
Topics: Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2001 |
Atypical multidrug resistance may be associated with catalytically active mutants of human DNA topoisomerase II alpha.
Topics: Amino Acid Substitution; Amsacrine; Antigens, Neoplasm; Catalysis; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Superhelical; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Etoposide; Gene Expression Regulation, Enzymologic; Genotype; Humans; Isoenzymes; Mutation; Phenotype; Poly-ADP-Ribose Binding Proteins; Recombinant Proteins; Saccharomyces cerevisiae | 2001 |
Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Topics: Amsacrine; Anion Transport Proteins; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blotting, Northern; Breast Neoplasms; Carcinoma; Carrier Proteins; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Isoenzymes; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 2001 |
Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Topics: Adenoviridae; Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Gene Transfer Techniques; Genetic Vectors; Humans; Isoenzymes; Tumor Cells, Cultured | 2001 |
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Carcinoma; Clone Cells; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Induction; Enzyme Inhibitors; Etoposide; Female; Humans; Mitoxantrone; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; RNA, Messenger; RNA, Neoplasm; Selection, Genetic; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vincristine | 2001 |
Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; DNA Mutational Analysis; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Mutation; Nuclease Protection Assays; Ribonucleases; RNA, Neoplasm; Sequence Deletion; Tumor Cells, Cultured | 2001 |
Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Topics: Amsacrine; Animals; Base Sequence; Biopolymers; DNA Topoisomerases, Type II; DNA, Neoplasm; Etoposide; Leukemia L1210; Magnetic Resonance Spectroscopy; Molecular Sequence Data; Topoisomerase II Inhibitors; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2000 |
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool; Cytarabine; Down Syndrome; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Thioguanine; Vincristine | 2002 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
Luteolin, an emerging anti-cancer flavonoid, poisons eukaryotic DNA topoisomerase I.
Topics: Amsacrine; Animals; Antineoplastic Agents; Base Sequence; Betulinic Acid; Catalysis; Cell Nucleus; DNA, Superhelical; Enzyme Inhibitors; Etoposide; Flavonoids; Kinetics; Liver; Luteolin; Nucleic Acid Denaturation; Oligodeoxyribonucleotides; Pentacyclic Triterpenes; Plant Leaves; Quercetin; Rats; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Triterpenes | 2002 |
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neutrophils; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2003 |
Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
Topics: Amsacrine; Animals; Antineoplastic Agents; Carbazoles; Colonic Neoplasms; Cross-Linking Reagents; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Humans; In Vitro Techniques; Leukemia P388; Mice; Mice, Inbred C57BL; Pyrimidines; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Betamethasone; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Mitoxantrone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous; Vincristine | 2002 |
[Effect of etoposide and amsacrine on mitotic progression of GM-130 and Hep-2 cell lines. The flow cytometry assay].
Topics: Amsacrine; Enzyme Inhibitors; Etoposide; Flow Cytometry; G2 Phase; Humans; Mitosis; Mitotic Index; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2003 |
Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Topics: Amsacrine; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Fibroblasts; Fluorescein-5-isothiocyanate; Fluorescent Antibody Technique; Fluorescent Dyes; Half-Life; Isoenzymes; Kinetics; Mice; Mitoxantrone | 2004 |
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous | 2004 |
Investigations into the biological relevance of in vitro clastogenic and aneugenic activity.
Topics: Alkylating Agents; Amsacrine; Aneuploidy; Cells, Cultured; Chromosome Aberrations; Chromosomes, Human; Cytochalasin B; DNA Damage; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Gene Expression Profiling; Guanine; Humans; Lymphocytes; Methyl Methanesulfonate; Micronucleus Tests; Mutagens; Oxyquinoline; Risk; Topoisomerase II Inhibitors | 2004 |
Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
Topics: Amino Acid Sequence; Amsacrine; Antineoplastic Agents; DNA; DNA Topoisomerases, Type II; Enzyme Stability; Etoposide; Glutamic Acid; Humans; Lysine; Models, Molecular; Mutation; Topoisomerase II Inhibitors; Tranexamic Acid | 2004 |
Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.
Topics: Amino Acid Sequence; Amino Acid Substitution; Amsacrine; Antineoplastic Agents; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Etoposide; Molecular Sequence Data; Mutagenesis; Mutation; Protein Structure, Tertiary; Saccharomyces cerevisiae; Topoisomerase II Inhibitors | 2005 |
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Proliferation; Cytarabine; Daunorubicin; DNA; Etoposide; Flow Cytometry; Fluorescent Dyes; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hydrocarbons, Chlorinated; Leukemia; Leukemia, Myeloid, Acute; Microscopy, Fluorescence; Oligopeptides; Organic Chemicals; Radiation-Protective Agents | 2005 |
Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Drug Evaluation; Drug Synergism; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia-Lymphoma, Adult T-Cell; Male; Methylprednisolone; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recombinant Proteins; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Thiotepa; Topotecan; Treatment Outcome; Vidarabine; Vinblastine | 2005 |
Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.
Topics: Amsacrine; Antineoplastic Agents; Digitoxin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoposide; Humans; Idarubicin; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitoxantrone; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2006 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Cytarabine; Daunorubicin; Developing Countries; Disease-Free Survival; Drug Evaluation; Etoposide; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Infant; Infections; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Mercaptopurine; Methotrexate; Mitoxantrone; Prednisone; Remission Induction; Retrospective Studies; Singapore; Survival Analysis; Thioguanine; Treatment Outcome; Vincristine | 2007 |
Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Topics: Amsacrine; Antineoplastic Agents; Cell Survival; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Gene Expression Regulation, Fungal; Nucleic Acid Synthesis Inhibitors; Rad52 DNA Repair and Recombination Protein; Recombination, Genetic; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Topoisomerase II Inhibitors | 2006 |
Zygomycosis in the immunocompromised patient: a case report.
Topics: Absidia; Acute Disease; Aerosols; Amphotericin B; Amsacrine; Antibiotic Prophylaxis; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Daunorubicin; Debridement; Drug Resistance, Fungal; Drug Resistance, Neoplasm; Etoposide; Fluconazole; Humans; Immunocompromised Host; Leukemia; Liposomes; Middle Aged; Mucormycosis; Sinusitis; Tomography, X-Ray Computed | 2006 |
Topoisomerase II and tubulin inhibitors both induce the formation of apoptotic topoisomerase I cleavage complexes.
Topics: Amino Acid Chloromethyl Ketones; Amsacrine; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Doxorubicin; Enzyme Inhibitors; Etoposide; HL-60 Cells; Humans; Paclitaxel; Reactive Oxygen Species; Topoisomerase II Inhibitors; Tubulin Modulators; Vinblastine | 2006 |
Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs.
Topics: Amsacrine; Animals; Antineoplastic Agents; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Ellipticines; Etoposide; Humans; Immunoblotting; Mice; Microscopy, Confocal; Mitoxantrone; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
[A case of unclassified B-cell lymphosarcoma].
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cytarabine; Diagnosis, Differential; Etoposide; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Middle Aged; Remission Induction; Tomography, X-Ray Computed | 2008 |
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Gemtuzumab; Humans; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Neoplasm Staging; Pilot Projects; Prognosis; Survival Rate; Young Adult | 2012 |
Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2013 |
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cytarabine; Daunorubicin; Drug Therapy, Combination; Egg Hypersensitivity; Etoposide; Female; Food Hypersensitivity; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Immunosuppressive Agents; Intestinal Diseases; Leukemia, Myeloid, Acute; Liver Diseases; Male; Middle Aged; Nut Hypersensitivity; Seafood; Tacrolimus; Transplantation Conditioning; Vidarabine | 2014 |
Amsacrine-induced apoptosis of human leukemia U937 cells is mediated by the inhibition of AKT- and ERK-induced stabilization of MCL1.
Topics: Amsacrine; Antineoplastic Agents; Apoptosis; Calcium; Etoposide; Extracellular Signal-Regulated MAP Kinases; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; NIMA-Interacting Peptidylprolyl Isomerase; Phosphorylation; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; Protein Stability; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Recombinant Proteins; Signal Transduction; U937 Cells | 2017 |